May 2009 Clinical Laboratory News: Volume 35, Number 5

CLN Banner Logo


The BNP Debate
How Important is this Biomarker in Diagnosing Heart Failure?
By Gina Rollins


BNP and NT-proBNP stand out among a constellation of biomarkers that have been investigated for diagnosing, staging and assessing the risk of heart failure progression. However, heart failure remains a clinically defined disease, leaving clinicians with questions about how best to use BNP and NT-proBNP.

Comparative Effectiveness
Where do Labs Fit in?

By Bill Malone


With over $1 billion in new funds available, comparative effectiveness research is gaining new prominence as Congress looks toward healthcare reform. Laboratorians can build upon current evidence-based medicine approaches to be a part of this push for greater focus on outcomes and evidence.


Heparin-Induced Thrombocytopenia
How Lab Results Contribute to Clinicopathologic Diagnosis

By Kristi J. Smock, MD, and George M. Rodgers, MD, PhD


As one of the most widespread drugs used today, heparin is an essential part of modern medicine. Unfortunately, its use is occasionally accompanied by immune-mediated thrombocytopenia and thrombosis. Diagnosing heparin-induced thrombocytopenia is not a simple process.


New Study Shows Growing Burden of Diabetes


New Products

Regulatory Profiles

Industry Profiles

Diagnostic Profiles

News from the FDA

Page Access:

Next Month

Ethics and the Diagnostics Industry

PSA and Beyond: The Latest on Prostate Cancer Screening